Metagenomi Therapeutics, Inc. (MGX)

NASDAQ: MGX · USD

$0.83

+0.03 (+4.1%)· Recorded snapshot

Market cap	31.5M
Revenue (ttm)	13.6M
Net income (ttm)	-93.5M
EPS (ttm)	-$2.49
Shares out	37.8M
Volume	121,155
Beta	0.70

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 13.6M
Net income (ttm): -93.5M
EPS (ttm): -$2.49
Market cap: 31.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-60.6

P25 n/aP50 n/aP75 n/a

ROIC-32.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MGX indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001785279
Company name	Metagenomi Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	59102M104
Earnings date	2026-11-10
Earnings time	amc
Employees	113
Employees change	-58
Employees growth	-33.92%
Enterprise value	$-51.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
Industry	Biotechnology
IPO date	2024-02-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US59102M1045
Last 10-K release date	2026-03-05
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$31.5M
Market cap category	Nano-Cap
Next earnings date	2026-11-10
Options	No
Price	$0.83
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	MGX
U.S. state	California
Website	https://metagenomi.co

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-299.03%
FCF / EV yield	164.98%
FCF yield	-277.3%
Forward P/S	3.28x
P/B ratio	0.27x
P/S ratio	2.28x
Price / tangible book value	0.27x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-741.58%
Pretax margin	-690.6%
Profit per employee	$-827,097
Revenue per employee	$120,009
ROA	-28.19%
ROCE	-68.85%
ROE	-60.61%
ROIC	-32.31%
SBC / revenue	77.6%
Tax / revenue	-1.4%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	-59.84%
Revenue growth 3Y	-23.68%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-309,000
Depreciation and amortization	$5.2M
EBIT	$-100.6M
EBITDA	$-95.4M
EPS	$-2.49
FCF per share	$-2.27
Financing cash flow	$-73,000
Free cash flow	$-85.8M
Free cash flow minus SBC	$-96.3M
Gross profit	$-75M
Income taxes	$-190,000
Investing cash flow	$96.9M
Net cash flow	$11.3M
Net income	$-93.5M
Operating cash flow minus SBC	$-96M
Operating income	$-100.6M
Revenue	$13.6M
Stock-based compensation	$10.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.42
Book value per share	$2.98
Debt / equity	0.34
Long-term assets	$49.2M
Long-term liabilities	$33.5M
Net cash (debt)	$82.9M
Net cash / market cap	268.08%
Net cash growth	-48.8%
Net debt / equity	-0.74
Piotroski F-Score	1
Property, plant and equipment	$41.7M
Shareholders' equity	$112.6M
Tangible book value	$112.6M
Tangible book value per share	$2.98
Total assets	$173.7M
Total cash	$120.7M
Total debt	$37.7M
Total liabilities	$61.1M
WACC	3.66%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.06
Current assets	$124.5M
Current liabilities	$27.6M
Current ratio	4.5
Net working capital	$-17.6M
Quick ratio	4.4
Working capital	$96.8M
Working capital turnover	0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.07%
Dividend yield	0%
Shareholder yield	-1.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.22
1D price change	4.14%
1M price change	-27.56%
1M total return	-27.56%
1W price change	0.52%
1W total return	0.52%
1Y price change	-69.59%
1Y return CAGR	-69.62%
1Y total return	-69.59%
20-day SMA	$0.90
200-day SMA	$1.30
3M price change	-31.15%
3M total return	-31.15%
50-day SMA	$1.06
50-day SMA vs 200-day SMA	50under200
52-week high	$2.78
52-week high date	2025-10-28
52-week low	$0.75
52-week low date	2026-10-27
6M price change	-43.71%
6M total return	-43.71%
All-time high	$12.74
All-time high date	2024-02-15
All-time low	$0.75
All-time low date	2026-10-26
Average true range (ATR)	$0.06
Average volume	173.3K
Beta (1Y)	2.1
Beta (2Y)	1.04
Beta (5Y)	0.7
Change from 52-week high	-70.03%
Change from 52-week low	11.08%
Change from all-time high	-93.46%
Change from all-time low	11.08%
Change from open	4.14%
Day's gap	0%
Dollar volume	$100,934
High price	$0.83
Low price	$0.80
Monthly RSI	21.74
Open price	$0.80
Position in 52-week range	100%
Premarket change	6.8%
Premarket close	$0.80
Premarket price	$0.85
Premarket volume	3K
Previous close	$0.80
Price vs 150-day SMA	-31.82%
Price vs 20-day SMA	-7.91%
Price vs 200-day SMA	-36.06%
Price vs 50-day SMA	-21.41%
Relative volume	0.7
Return from IPO open	-92.01%
Return from IPO price	-94.54%
RSI	36.19
Sharpe ratio	-1.95
Sortino ratio	-2.41
Volume	121.2K
Weekly RSI	27.63
YTD price change	-48.57%
YTD total return	-48.57%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	25.5M
Float percentage	67.61%
Shares change (QoQ)	0.21%
Shares change (YoY)	1.07%
Shares held by insiders	10.57%
Shares held by institutions	17.12%
Shares outstanding	37.8M
Short % of float	4.98%
Short % of shares	3.37%
Short ratio	8.2 days

Deeper analysis on MGX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MGX report

Is a complete MGX research report available?

No complete published report is available for Metagenomi Therapeutics, Inc. (MGX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Metagenomi Therapeutics, Inc. (MGX)

Price

Financial snapshot

Fair-value bridge

Latest news · MGX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MGX

Frequently asked questions